Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 5 ( May, 2022 ) > List of Articles

Original Article

The Dominance of Candida auris: A Single-center Experience of 79 Episodes of Candidemia from Western India

Parikshit S Prayag, Sampada Patwardhan, Shweta Panchakshari, Prasad A Rajhans, Amrita Prayag

Keywords : Candida, Candida auris, Candidemia, Invasive candidiasis

Citation Information : Prayag PS, Patwardhan S, Panchakshari S, Rajhans PA, Prayag A. The Dominance of Candida auris: A Single-center Experience of 79 Episodes of Candidemia from Western India. Indian J Crit Care Med 2022; 26 (5):558-561.

DOI: 10.5005/jp-journals-10071-24152

License: CC BY-NC 4.0

Published Online: 30-04-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Introduction: Invasive candidiasis is a serious infection seen in hospitalized or immunocompromised patients. Mortality rates for candidemia can be as high as 30–60%. Candida auris is an emerging species of candida and is increasingly becoming a global public health problem. Methods: This was a retrospective observational study, in which we analyzed 79 episodes of candidemia. Blood cultures were done using the Bactec™ FX blood culturing instrument (Becton, Dickinson and Company Sparks, Maryland, USA). Species identification was done using VITEK® 2 YST panels (bioMérieux Inc., Durham, North Carolina, USA). Antifungal susceptibility testing was performed using VITEK® 2 AST-YSO8 panels (bioMérieux Inc., Durham, North Carolina, USA). Results: Among the 79 episodes, the most common species was found to be C. auris (43.03% of all the episodes). Candida tropicalis was found to be the second most common species in patients admitted to our hospital with candidemia. All the isolates of C. auris were resistant to fluconazole, while 32.35 % of the isolates were also resistant to amphotericin B. Crude mortality in patients with C. auris candidemia was higher than the crude mortality for the other species. Conclusion: This is the first study from India where C. auris was seen as the most predominant species among patients admitted with candidemia. This is a serious issue given the high rates of fluconazole resistance, mortality, and cost of therapy associated with C. auris bloodstream infections. Urgent attention needs to be diverted to infection control practices and antimicrobial stewardship programs.

  1. Flevari A, Theodorakopoulou M, Velegraki A, Armaganidis A, Dimopoulos G. Treatment of invasive candidiasis in the elderly: a review. Clin Interv Aging 2013;8:1199–1208. DOI: 10.2147/CIA.S39120.
  2. Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015;41(2):285–295. DOI: 10.1007/s00134-014-3603-2.
  3. Mathur P, Hasan F, Singh PK, Malhotra R, Walia K, Chowdhary A. Five-year profile of candidemia at an Indian trauma centre: High rates of Candida auris blood stream infections. Mycoses 2018;61(9):674–680. DOI: 10.1111/myc.12790.
  4. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009;53(1):41–44. DOI: 10.1111/j.1348-0421.2008.00083.x.
  5. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 2017;64(2):134–140. PMID: 27988485.
  6. Chow NA, de Groot T, Badali H, Abastabar M, Chiller TM, Meis JF. Potential fifth clade of Candida auris, Iran, 2018. Emerg Infect Dis 2019;25(9):1780–1781. PMID: 31310230.
  7. Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother 2018;73(4):891–899. DOI: 10.1093/jac/dkx480.
  8. Arendry MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of EUCAST and CLSI reference microdilution MICS of eight antifungal compounds for C. auris and associated tentative epidemiological cut off values. Antimicrob Agents Chemother 2017;61:e00485–e00517. DOI: 10.1128/AAC.00485-17.
  9. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4):e1–e50. DOI: 10.1093/cid/civ933.
  10. Kobayashi T, Marra AR, Schweizer ML, Eyck PT, Wu C, Alzunitan M, et al. Impact of infectious disease consultation in patients with candidemia: a retrospective study. Systematic literature review, and meta-analysis. Open Forum Infect Dis 2020;7(9):ofaa270. DOI: 10.1093/ofid/ofaa270.
  11. Astvad KM, Perlin DS, Johansen HK, Jensen RH, Arendrup MC. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species. Antimicrob Agents Chemother 2013;57(1):177–182. DOI: 10.1128/AAC.01382-12.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.